Mavacamten
Mavacamten (Camzyos) is a cardiac myosin inhibitor used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, a thickened-heart-muscle condition that blocks blood flow out of the heart.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Mavacamten (Camzyos), on the U.S. market since about 2021, is a specialist medicine for adults with symptomatic obstructive hypertrophic cardiomyopathy (a thickened heart muscle that blocks blood leaving the heart), usually added when beta blockers or similar drugs are not enough; it calms cardiac myosin, the protein behind each squeeze, so blood flows out more freely. It is generally well tolerated, though dizziness or fainting can occur. The catch is its boxed warning for heart failure, since it can weaken the heart's pumping strength, so echocardiograms (heart ultrasounds) are required before and during treatment and new breathlessness, leg swelling or unusual tiredness should be reported promptly.
Clinical pearls
- Starting or stopping other medicines can raise its levels or blunt it, so have every change, including over-the-counter products, checked first.
- Remind other prescribers to avoid disopyramide, ranolazine, and verapamil or diltiazem combined with a beta blocker while you take it.
- It may weaken some combined birth control (ethinyl estradiol with norethindrone excepted), and contraception must continue 4 months after the last dose.
- A serious infection or new atrial fibrillation (irregular heartbeat) raises heart failure risk, so tell your cardiologist, who may pause it.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Camzyos can cause heart failure by weakening the heart's pumping strength. Your heart will be checked with echocardiograms before and during treatment. Starting or increasing the dose depends on these results.
Your risk is higher with a serious illness or an irregular heartbeat, or if you take certain interacting medicines. Watch for shortness of breath, chest pain, unusual tiredness, palpitations, and leg swelling, and report them promptly.
Patient information guide A plain-language walkthrough of Mavacamten, written from its FDA label.
What Mavacamten is used for
▾
Mavacamten is used for one condition.
- Camzyos is used in adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
How Mavacamten works
▾
Mavacamten is a cardiac myosin inhibitor. In HCM, heart muscle proteins form too many links that make the muscle contract too forcefully and relax poorly. Mavacamten reversibly reduces these links and shifts the muscle toward a more relaxed, energy-saving state.
This reduces the blockage of blood flow out of the heart (LVOT obstruction) and improves filling pressures.
Mavacamten dosage
▾
Camzyos is a capsule taken by mouth once daily. Your dose is individualized based on how you feel and on echocardiogram results, so regular heart checks are part of treatment.
- Food does not significantly change how much drug your body absorbs.
- Women who can become pregnant should confirm they are not pregnant before starting.
- Follow your prescriber and the label exactly.
Dosing details from the FDA-approved label
From the Mavacamten prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
The recommended starting dose is 5 mg orally once daily without regard to food; allowable subsequent doses with titration are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily.
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Dosage must be individualized based on clinical status and echocardiographic assessment of patient response. Refer to the Full Prescribing Information for instructions. ( 2.1 ) 2.1 Initiation, Maintenance, and Interruption of Treatment Confirm absence of pregnancy and usage of effective contraception in females of reproductive potential [see Warnings and Precautions (5.4) ] . Initiation or up-titration of CAMZYOS in patients with LVEF <55% is not recommended. The recommended starting dose is 5 mg orally once daily without regard to food; allowable subsequent doses with titration are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily. Patients may develop heart failure while taking CAMZYOS. Regular LVEF and Valsalva left ventricular outflow tract (LVOT) gradient assessment is required for careful titration to achieve an appropriate target Valsalva LVOT gradient, while maintaining LVEF ≥50% and avoiding heart failure symptoms (see Figure 1 and Figure 2). Daily dosing takes weeks to reach steady-state drug levels and therapeutic effects, and genetic variation in metabolism and drug interactions can cause large differences in exposure [see Boxed Warning , Contraindications (4) , Warnings and Precautions (5.2) , Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . When initiating or titrating CAMZYOS, first consider LVEF then consider the Valsalva LVOT gradient and patient clinical status to guide appropriate CAMZYOS dosing. Assessment of post-exercise LVOT gradient may be considered in symptomatic patients with normal or near normal Valsalva gradients (approximately 30 mmHg) prior to initiating treatment with CAMZYOS. Follow the algorithms for Initiation (Figure 1) and Maintenance (Figure 2) for appropriate CAMZYOS dosing and monitoring schedules. If LVEF <50% while taking CAMZYOS, interrupt treatment. Follow the algorithm for Interruption (Figure 3) for guidance on interrupting, restarting, or discontinuing CAMZYOS. If interrupted at 2.5 mg, either restart at 2.5 mg or discontinue permanently.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Mavacamten side effects
▾
The most common side effects in studies were:
Common side effects
- Dizziness
- Fainting (syncope)
When to get medical help
- Call your doctor right away if you have new or worsening shortness of breath, chest pain, unusual tiredness, or leg swelling. These can be signs of heart failure.
- Get help for a racing, pounding, or irregular heartbeat (palpitations or new arrhythmia).
- Tell your doctor if you faint or feel like you might.
- Tell your doctor if you develop a serious illness such as a serious infection. Your doctor may need to pause the medicine.
- Call your doctor if you become pregnant or think you might be.
- In an overdose or accidental ingestion, call Poison Help at 1-800-222-1222 or seek emergency care.
Fainting was the only side effect that led people to stop the drug in the main trial. Heart failure symptoms need prompt attention.
Mavacamten warnings and precautions
▾
- Heart failure: Camzyos lowers the heart's squeezing function. Heart function is checked before and regularly during treatment.
- Serious illness (such as a serious infection) or irregular heartbeat such as atrial fibrillation raises the risk. Your doctor may pause treatment during illness.
- Warning signs include new or worsening shortness of breath, chest pain, fatigue, palpitations, leg swelling, or arrhythmia.
- Drug interactions, including with over-the-counter medicines, can cause heart failure or reduce effectiveness.
- It may cause fetal harm, so effective contraception is needed.
Mavacamten interactions
▾
Many medicines change mavacamten levels, so always check before starting something new.
- Strong CYP2C19 inhibitors: must not be used. They raise drug levels and heart failure risk.
- Moderate to strong CYP2C19 or CYP3A4 inducers: must not be used. They lower the drug's effect.
- Weak to moderate CYP2C19 inhibitors and moderate to strong CYP3A4 inhibitors: can raise levels. Dose reduction and extra monitoring are needed.
- Disopyramide, ranolazine, verapamil with a beta blocker, and diltiazem with a beta blocker: avoid. They add to the weakening of the heart's pumping.
- Other drugs that reduce heart contraction: LVEF is monitored closely.
- Some combined hormonal birth control: may become less effective. Add nonhormonal contraception unless it contains ethinyl estradiol with norethindrone.
Interactions listed in the FDA-approved label
From the Mavacamten prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP2C19 inhibitors: Increases mavacamten exposure, which may increase the risk of heart failure due to systolic dysfunction. Concomitant use with a strong CYP2C19 inhibitor is contraindicated.
- Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers: Decreases mavacamten exposure, which may reduce CAMZYOS' efficacy; the risk of heart failure due to systolic dysfunction may increase with discontinuation of these inducers. Concomitant use of a moderate to strong CYP2C19 inducer or a moderate to strong CYP3A4 inducer is contraindicated.
- Weak CYP2C19 inhibitors or moderate CYP3A4 inhibitors: Increases mavacamten exposure, which may increase the risk of adverse drug reactions. Initiate CAMZYOS at 5 mg orally once daily in patients on stable therapy with the inhibitor. Reduce to the next lower daily dose level (15 mg to 10 mg, 10 mg to 5 mg, or 5 mg to 2.5 mg) in patients on CAMZYOS who intend to start the inhibitor. Avoid initiating the inhibitor in patients on stable treatment with 2.5 mg because a lower dose is not available. Fo
- Moderate CYP2C19 inhibitors or strong CYP3A4 inhibitors: Increases mavacamten exposure, which may increase the risk of adverse drug reactions; discontinuing the inhibitor after long-term use may decrease mavacamten exposure and reduce CAMZYOS' efficacy. Initiate CAMZYOS at 2.5 mg orally once daily in patients on stable therapy with the inhibitor. Reduce to the next lower daily dose level (15 mg to 10 mg, 10 mg to 5 mg, or 5 mg to 2.5 mg) in patients on CAMZYOS who intend to start the inhibitor. Avoid initiating the inhibitor in patients on stable treatment with 2.5 mg because a lower dose is not available.
- Certain CYP3A4, CYP2C9, and CYP2C19 substrates: Mavacamten is an inducer of CYP3A4, CYP2C9, and CYP2C19 and may reduce plasma concentration of these substrate drugs. Closely monitor when CAMZYOS is used with CYP3A4, CYP2C9 or CYP2C19 substrates unless otherwise recommended in the Prescribing Information.
- Certain combined hormonal contraceptives: CAMZYOS may decrease exposures of certain progestins, which may lead to contraceptive failure. Combined hormonal contraceptives containing ethinyl estradiol and norethindrone may be used with mavacamten; if other CHCs are used, add nonhormonal contraception (such as condoms) or use an alternative method not affected by CYP450 enzyme induction (e.g., intrauterine system) during concomitant use and for 4 months after the last dose of CAMZYOS.
- Disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker: Additive negative inotropic effects; these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms, and clinical experience is limited. Avoid concomitant use.
- Other negative inotropes (drugs that reduce cardiac contractility): Additive negative inotropic effects are expected with CAMZYOS. If a negative inotrope is initiated or its dose is increased, monitor LVEF closely until stable doses and clinical response have been achieved.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Weak to moderate CYP2C19 inhibitors and moderate to strong CYP3A4 inhibitors : May increase risk of heart failure. If initiating an inhibitor, CAMZYOS dose reduction and additional monitoring are required. ( 2.2 , 7.1 ) • Negative inotropes : Close medical supervision and LVEF monitoring is recommended if a negative inotrope is initiated, or the dose of a negative inotrope is increased. Avoid certain combinations of negative inotropes. ( 7.3 ) 7.1 Potential for Other Drugs to Affect Plasma Concentrations of CAMZYOS Mavacamten is primarily metabolized by CYP2C19 and to a lesser extent by CYP3A4 and CYP2C9. Inducers and inhibitors of CYP2C19 and moderate to strong inhibitors or inducers of CYP3A4 may affect the exposures of mavacamten [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] . (See Table 1 ) Table 1: Established and Potentially Significant Pharmacokinetic Drug Interactions with CAMZYOS Impact of Other Drugs on CAMZYOS Strong CYP2C19 Inhibitors Clinical Impact Concomitant use with a strong CYP2C19 inhibitor increases mavacamten exposure, which may increase the risk of heart failure due to systolic dysfunction [see Contraindications (4) , Warnings and Precautions (5.2) , Clinical Pharmacology (12.3) ] . Prevention or Management Concomitant use with a strong CYP2C19 inhibitor is contraindicated. Moderate to Strong CYP2C19 Inducers or Moderate to Strong CYP3A4 Inducers Clinical Impact Concomitant use with a moderate to strong CYP2C19 inducer or a moderate to strong CYP3A4 inducer decreases mavacamten exposure, which may reduce CAMZYOS’ efficacy [see Clinical Pharmacology (12.3) ] . The risk of heart failure due to systolic dysfunction may increase with discontinuation of these inducers as the levels of induced enzyme normalizes [see Contraindications (4) and Warnings and Precautions (5.2) ] .
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Mavacamten
▾
- Must not be used with strong CYP2C19 inhibitors, or with moderate to strong CYP2C19 or CYP3A4 inducers.
- Pregnancy: may cause fetal harm in animal studies. A pregnancy test is needed before starting, and contraception is advised during treatment and for 4 months after the last dose.
- Breastfeeding: it is unknown if the drug passes into milk or affects the baby.
- Children: safety and effectiveness have not been established.
- Older adults: safety and effectiveness were similar to younger adults.
- Liver: mild to moderate impairment does not need a dose change. Effects of severe impairment are unknown.
Mavacamten overdose
▾
Too much Camzyos can lower heart function, cause heart failure, low blood pressure, dizziness, and fainting. Serious cases can stop the heart. An infant died after accidentally swallowing three capsules.
Seek emergency care or call Poison Help at 1-800-222-1222. Treatment includes stopping the drug and supportive care, and sometimes activated charcoal soon after ingestion.
What Mavacamten does in the body
▾
In the EXPLORER-HCM trial, Camzyos reduced the pressure gradient across the heart's outflow area by Week 4, and the effect lasted through 30 weeks. It also lowered LVEF slightly, generally staying in the normal range. Eight weeks after stopping, LVEF and gradients returned to near baseline.
Heart stress markers such as NT-proBNP also fell more than with placebo. The clinical significance of some of these findings is unknown.
How your body processes Mavacamten
▾
Mavacamten is well absorbed by mouth, reaching peak blood levels in about 1 to 2 hours. A high-fat meal did not make a clinically significant difference. It is broken down mainly by the liver enzyme CYP2C19, plus CYP3A4 and CYP2C9.
Half-life is about 6 to 9 days in normal CYP2C19 metabolizers and about 23 days in poor metabolizers, so levels build up over time. Most of a dose leaves in urine, mostly as breakdown products.
How to store Mavacamten
▾
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Mavacamten
143 supplements and herbal products have documented interactions with Mavacamten in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 100
- Minor · 40
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Mavacamten: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Mavacamten — the kind of thing our pharmacy team would talk through with you at the counter.
What is Camzyos for?
▾
How do I take it?
▾
What side effects should I expect?
▾
Can I take other medicines or supplements with it?
▾
What if I get sick while on it?
▾
Is it safe in pregnancy?
▾
Is Mavacamten available over the counter?
▾
When was Mavacamten first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Mavacamten on HelloPharmacist
Mavacamten forms and strengths (how it comes)
Mavacamten is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Mavacamten inactive ingredients by manufacturer.
Capsule
How this form is used
- Camzyos is used for adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
- Camzyos is taken by mouth once daily.
- Camzyos dosing is individualized using symptoms and echocardiogram results.
- Camzyos can be taken with or without a high-fat meal without a clinically significant change in absorption.
Mavacamten on the U.S. market: products, makers and brands
How Mavacamten appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 4 Mavacamten product records with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2021. Brand names on the directory include Camzyos; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (9) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
How widely Mavacamten is used (Medicaid data)
A general measure of how commonly Mavacamten is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Mavacamten is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Mavacamten prescribed? Of the 1,601 medications we measure, Mavacamten ranks #1,095 by Medicaid prescriptions — more than 32% of them.
Utilization by Mavacamten product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
mavacamten 5 MG Oral Capsule Most dispensed
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2600888
mavacamten 10 MG Oral Capsule
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2600872
mavacamten 2.5 MG Oral Capsule
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2600884
mavacamten 15 MG Oral Capsule
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2600880
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Mavacamten, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 12 listed Mavacamten NDCs with Medicaid activity.
Compare Mavacamten products
A representative set of FDA-listed product records for Mavacamten — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 2.5 mg | Oral | Myokardia, Inc. | NDA | View NDC → |
| 5 mg | Oral | Myokardia, Inc. | NDA | View NDC → |
| 10 mg | Oral | Myokardia, Inc. | NDA | View NDC → |
| 15 mg | Oral | Myokardia, Inc. | NDA | View NDC → |
Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Mavacamten NDCs →
Mavacamten side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Mavacamten — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Mavacamten in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Mavacamten FDA approval history
How Mavacamten went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Mavacamten recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Mavacamten recalls since July 2021.
✅No Mavacamten recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2600867 1 dose form · 4 strengths
-
Dose form (SCDF) Oral Capsule RxCUI 2600871In current FDA listings
Look up RxCUI 2600867 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Mavacamten supply and shortage status
Whether Mavacamten is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Mavacamten brand names
Mavacamten is sold under one brand name in the FDA directory — Camzyos. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Mavacamten: manufacturers and labelers
One company lists Mavacamten products with the FDA. By number of product records, the largest are Myokardia, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Mavacamten drug class (RxNorm)
Mavacamten belongs to the Cardiac Myosin Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Mavacamten page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Myokardia, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →